在患有慢性心力衰竭的患者中,运动训练对左心室功能和外周阻力的影响:一项随机试验
R Hambrecht1, S Gielen, A Linke
1Klinik für Innere Medizin/Kardiologie, Universität Leipzig, Herzzentrum GmbH, Russenstrasse 19, 04289 Leipzig, Germany. hamr@server3.medizin.uni-leipzig.de
JAMA
|June 24, 2000
概括
在慢性心力衰竭患者中,运动训练显著改善运动能力和心脏功能. 这种干预减少了外围阻力,增加了中风体积,并减少了心脏大小.
科学领域:
- 心脏病学 心脏病学
- 运动生理学 运动生理学
- 心脏衰竭管理的管理
背景情况:
- 运动训练通过内皮功能和有氧新陈代谢改善慢性心力衰竭的能力.
- 运动训练对心力衰竭的核心血液动力学影响尚不清楚.
研究的目的:
- 评估运动训练对稳定的慢性心力衰竭患者左心室 (LV) 功能和血液动力学反应的影响.
主要方法:
- 一项前性随机试验,涉及73名患有慢性心力衰竭的男性患者 (年龄≤70岁).
- 干预:6个月的体能计运动训练与对照组相比.
- 结果测量:人体气管测量,中央血液动力学 (热稀释),心声回声学 (LV功能和维度).
主要成果:
- 运动组表现出功能类,运动能力和休息中风体积的改善.
- 在运动组中,LV射出分数显著增加 (0.30至0.35).
- 在训练组中,在运动的高峰期减少了外周总阻力 (TPR) 和增加了中风体积.
结论:
- 运动训练可以降低慢性心力衰竭中的外周抵抗力.
- 导致中风体积的显著改善,并减少心血管大病.
相关概念视频
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Exercise and Cardiovascular Response
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.


